ECSP055851A - DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS - Google Patents
DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESISInfo
- Publication number
- ECSP055851A ECSP055851A EC2005005851A ECSP055851A ECSP055851A EC SP055851 A ECSP055851 A EC SP055851A EC 2005005851 A EC2005005851 A EC 2005005851A EC SP055851 A ECSP055851 A EC SP055851A EC SP055851 A ECSP055851 A EC SP055851A
- Authority
- EC
- Ecuador
- Prior art keywords
- angiogenesis
- treatment
- pirazinona
- indolil
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Esta invención se refiere a un compuesto de Fórmula I (I)y su uso en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis.This invention relates to a compound of Formula I (I) and its use in the treatment of hyperproliferative disorders and diseases associated with angiogenesis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42549002P | 2002-11-12 | 2002-11-12 | |
US46091503P | 2003-04-07 | 2003-04-07 | |
US48420203P | 2003-06-30 | 2003-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055851A true ECSP055851A (en) | 2005-09-20 |
Family
ID=32314888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005851A ECSP055851A (en) | 2002-11-12 | 2005-06-10 | DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1565455A1 (en) |
JP (1) | JP2006509840A (en) |
KR (1) | KR20050072824A (en) |
AR (1) | AR043059A1 (en) |
AU (1) | AU2003290744A1 (en) |
BR (1) | BR0316169A (en) |
CA (1) | CA2505819A1 (en) |
EC (1) | ECSP055851A (en) |
HR (1) | HRP20050496A2 (en) |
MA (1) | MA27557A1 (en) |
MX (1) | MXPA05004779A (en) |
NO (1) | NO20052796L (en) |
PE (1) | PE20040832A1 (en) |
PL (1) | PL376867A1 (en) |
TW (1) | TW200418834A (en) |
UY (1) | UY28074A1 (en) |
WO (1) | WO2004043950A1 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
BRPI0416206A (en) * | 2003-11-20 | 2006-12-26 | Janssen Pharmaceutica Nv | 6-Alkenyl and 6-phenylalkyl-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors |
SG150534A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp- ribose) polymerase inhibitors |
EP1687313A1 (en) * | 2003-11-21 | 2006-08-09 | Bayer Pharmaceuticals Corporation | Indolyl-thien 3,4-b]pyrazin-3-one derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
AU2005259192C1 (en) | 2004-06-30 | 2012-03-01 | Janssen Pharmaceutica N.V. | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors |
BRPI0512938A (en) | 2004-06-30 | 2008-04-15 | Janssen Pharmaceutica Nv | quinazolinedione derivatives as inhibitors of |
CN1980674B (en) | 2004-06-30 | 2011-05-25 | 詹森药业有限公司 | Phthalazine derivatives as parp inhibitors |
JP6097946B2 (en) * | 2004-11-17 | 2017-03-22 | レクサン ファーマシューティカルズ インコーポレイテッド | 1-[(6,7-Substituted-alkoxyquinoxalinyl) aminocarbonyl] -4- (hetero) arylpiperazine derivatives |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
EP2757099B1 (en) | 2005-05-12 | 2017-08-23 | AbbVie Bahamas Limited | Apoptosis promoters |
US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
SI2134691T1 (en) | 2007-03-08 | 2012-06-29 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp and tank inhibitors |
CN101981013B (en) | 2008-03-27 | 2013-05-29 | 詹森药业有限公司 | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors |
WO2010053757A1 (en) * | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
US20100113514A1 (en) | 2008-10-30 | 2010-05-06 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
US20100120778A1 (en) * | 2008-11-07 | 2010-05-13 | Wyeth | Quinoxaline-based lxr modulators |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
KR102479696B1 (en) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Combinations of an fgfr inhibitor and an igf1r inhibitor |
EP3131881A4 (en) * | 2014-04-18 | 2017-09-06 | Millennium Pharmaceuticals, Inc. | Quinoxaline compounds and uses thereof |
CA2974078A1 (en) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
CA2996989C (en) | 2015-09-23 | 2023-10-03 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
HUE050567T2 (en) | 2015-09-23 | 2020-12-28 | Janssen Pharmaceutica Nv | Tricyclic heterocycles for the treatment of cancer |
AU2022354321A1 (en) * | 2021-09-29 | 2024-04-04 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta |
WO2024069592A1 (en) * | 2022-09-29 | 2024-04-04 | Repare Therapeutics Inc. | N-(5-substituted-[(l,3,4-thiadiazolyl) or (l,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW472045B (en) * | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
-
2003
- 2003-11-05 AR ARP030104059A patent/AR043059A1/en unknown
- 2003-11-10 MX MXPA05004779A patent/MXPA05004779A/en not_active Application Discontinuation
- 2003-11-10 WO PCT/US2003/036003 patent/WO2004043950A1/en active Application Filing
- 2003-11-10 EP EP03783328A patent/EP1565455A1/en not_active Withdrawn
- 2003-11-10 CA CA002505819A patent/CA2505819A1/en not_active Abandoned
- 2003-11-10 BR BR0316169-2A patent/BR0316169A/en not_active Application Discontinuation
- 2003-11-10 AU AU2003290744A patent/AU2003290744A1/en not_active Abandoned
- 2003-11-10 KR KR1020057008396A patent/KR20050072824A/en not_active Application Discontinuation
- 2003-11-10 PL PL376867A patent/PL376867A1/en unknown
- 2003-11-10 JP JP2005507146A patent/JP2006509840A/en active Pending
- 2003-11-11 TW TW092131443A patent/TW200418834A/en unknown
- 2003-11-11 UY UY28074A patent/UY28074A1/en not_active Application Discontinuation
- 2003-11-11 PE PE2003001136A patent/PE20040832A1/en not_active Application Discontinuation
-
2005
- 2005-06-02 HR HR20050496A patent/HRP20050496A2/en not_active Application Discontinuation
- 2005-06-09 MA MA28322A patent/MA27557A1/en unknown
- 2005-06-09 NO NO20052796A patent/NO20052796L/en not_active Application Discontinuation
- 2005-06-10 EC EC2005005851A patent/ECSP055851A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20052796D0 (en) | 2005-06-09 |
PL376867A1 (en) | 2006-01-09 |
AR043059A1 (en) | 2005-07-13 |
UY28074A1 (en) | 2004-05-31 |
KR20050072824A (en) | 2005-07-12 |
MA27557A1 (en) | 2005-10-03 |
CA2505819A1 (en) | 2004-05-27 |
PE20040832A1 (en) | 2005-01-27 |
EP1565455A1 (en) | 2005-08-24 |
BR0316169A (en) | 2005-09-27 |
NO20052796L (en) | 2005-06-09 |
MXPA05004779A (en) | 2005-07-22 |
TW200418834A (en) | 2004-10-01 |
HRP20050496A2 (en) | 2006-06-30 |
WO2004043950A1 (en) | 2004-05-27 |
JP2006509840A (en) | 2006-03-23 |
AU2003290744A1 (en) | 2004-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055851A (en) | DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | |
ECSP045081A (en) | DERIVATIVES OF 1,8-NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS | |
UY29983A1 (en) | DERIVATIVES OF 4-AMINO-PIRROLOTRIAZINE REPLACED USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | |
SV1999000047A (en) | NEW DIHYDROPYRIMIDINES FEF. READ 32792-SV | |
UY28014A1 (en) | CHEMICAL COMPOUNDS | |
ECSP066717A (en) | SUBSTITUTED QUINOLINE COMPOUNDS | |
ECSP056210A (en) | PREPARATION AND USE OF RENTAL DERIVATIVES FOR THE TREATMENT OF OBESITY | |
UY28290A1 (en) | NEW PHARMACEUTICAL COMPOUNDS | |
UY27793A1 (en) | PIRAZOLOPIRIDINS SUBSTITUTED WITH CARBAMATE | |
PA8565901A1 (en) | DERIVATIVES OF DIHIDROBENZODIAZEPIN-2-ONA III | |
ECSP088283A (en) | PIRIDINE COMPOUNDS 5- (PHENYLISOXAZOLILETOXI) -TRIAZOL- 3-ILO SUBSTITUTED FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | |
CR9034A (en) | PREPARATION AND USE OF BIFENIL-4-IL-CARBONYLAMINE ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | |
PA8543301A1 (en) | DERIVATIVES OF DIHIDRO-BENZO (B) (1,4) DIAZEPIN-2 -ONA AS ANTAGONISTS II MGLUR2 | |
HN2004000319A (en) | "{1,8} NAFTIRIDIN-2-ONAS AND RELATED COMPOUNDS FOR THE TREATMENT OF CHICHOPHRENIA" | |
DOP2002000429A (en) | IMIDAZOTRIAZINAS | |
ECSP045156A (en) | INDOLILALQUILAMINE DERIVATIVES AS LIGANDOS 5-HIDROXITRIPTAMINA-6 | |
CY1109992T1 (en) | Alpha-aminamide derivatives useful as anti-inflammatory agents | |
HN2003000379A (en) | USEFUL ANILINOPIRAZOL DERIVATIVES IN THE TREATMENT OF DIABETES | |
HN2003000080A (en) | INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS AND PROCEDURES FOR USE | |
UY27203A1 (en) | USEFUL BENCIMIDAZOLS IN THE TREATMENT OF SEXUAL DYSFUNCTION | |
SV2006002238A (en) | INHIBITORS OF THE SOLUBLE CYCLING ADENYLATE REF. P-SV-78. 959 / GH | |
ECSP056174A (en) | USEFUL HYDROXAMIC ACIDS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | |
UY27733A1 (en) | CYCLOPENTENE DERIVATIVES | |
CR7835A (en) | USE OF LEVOCETIRICINE FOR THE TREATMENT OF PERSISTENT ALLERGIC RHINITIS | |
DOP2003000749A (en) | DERIVATIVES OF INDOLIL PIRAZINONA UTILE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |